Long-term study of people with ATTR amyloidosis in routine care
Follows people with ATTR amyloidosis, including treatment with patisiran or vutrisiran.
Key facts
- Who runs it
- Alnylam Pharmaceuticals
- Where
- Berlin, Giessen, and Hanover, GermanySee the 3 sitesAlso in 11 other countries, 37 sites
- Trial code
- Registry title
- ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- 23 Nov 2020
- Expected to end
- 31 Dec 2033
- Type of study
- Observational, 2 groups
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for people with ATTR amyloidosis, or people who carry a known disease-causing TTR variant but have no symptoms yet.
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of ATTR amyloidosis, or a documented known disease-causing TTR variant for carriers without symptoms.
- Earlier treatment
- In Germany only, people must be treated as set out in the summary of product characteristics for an approved ATTR amyloidosis treatment.
- Biomarker or test result
- A documented known disease-causing TTR variant is needed for the group of carriers without symptoms.
Main reasons for not taking part
- Currently taking part in a clinical trial of any investigational agent
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
- Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis
Who cannot take part
- Current enrollment in a clinical trial for any investigational agent
Where in Germany
Also in 11 other countries, 37 sites
- BerlinHospital not named in the registryTaking people
- GiessenHospital not named in the registryTaking people
- Hanover, HannoverHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The purpose of this study is to:
Read full original descriptionShow less
* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
The 2 groups in the trial
- Patients with ATTR amyloidosis
Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
- Pre-symptomatic Carriers
Pre-symptomatic carriers with a known disease-causing TTR variant will be eligible for the study and will follow routine clinical care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Plain-language title
- Long-term study of people with ATTR amyloidosis in routine careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 October 2026